We could not find any results for:
Make sure your spelling is correct or try broadening your search.
TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network Research...
This late-stage clinical trial company focuses on preventing inflammation and acute organ injury. It is developing a platform of new drugs to prevent inflammation in the kidneys, liver and lungs...
TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun...
TORONTO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement...
TORONTO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has closed a transaction that...
TORONTO, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a transaction to...
TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Alberta Health Services (AHS) has approved...
Arch is repurposing cilastatin, a dipeptidase-1 inhibitor, as a new treatment for acute kidney injury (AKI)Cilastatin is particularly well suited to prevent AKI caused by drug toxins due to its...
TORONTO, July 30, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has closed the non-brokered private placement...
TORONTO, July 29, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has arranged a non-brokered private placement...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.06 | -3.09278350515 | 1.94 | 1.95 | 1.83 | 20240 | 1.92148724 | CS |
4 | 0.1 | 5.61797752809 | 1.78 | 2.01 | 1.7 | 13877 | 1.90497329 | CS |
12 | -0.18 | -8.73786407767 | 2.06 | 2.1 | 1.59 | 16547 | 1.92897414 | CS |
26 | 0.27 | 16.7701863354 | 1.61 | 2.2 | 1.36 | 14892 | 1.7879115 | CS |
52 | 0.34 | 22.0779220779 | 1.54 | 2.56 | 1.36 | 19196 | 1.85162807 | CS |
156 | -1.72 | -47.7777777778 | 3.6 | 4.25 | 0.97 | 19565 | 2.17743219 | CS |
260 | 0.95 | 102.150537634 | 0.93 | 5.3 | 0.74 | 27076 | 1.99597729 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions